[{"id":"02699193-e287-431a-b255-1adc890318f2","acronym":"NCI-2018-00926","url":"https://clinicaltrials.gov/study/NCT03450122","created_at":"2021-01-19T15:37:56.641Z","updated_at":"2024-07-02T16:35:33.518Z","phase":"Phase 1","brief_title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","source_id_and_acronym":"NCT03450122 - NCI-2018-00926","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":"","alterations":" ","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-10-16"}]